NCT01773109View on ClinicalTrials.gov

Etirinotecan Pegol (NKTR-102) in NSCLC

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

January 31, 2016

Study Completion Date

March 15, 2017

Conditions
Metastatic Non Small Cell Lung CancerRecurrent Non Small Cell Lung Cancer
Interventions
DRUG

Etirinotecan pegol (NKTR-102)

Eligible patients will receive etirinotecan pegol at a dose of 145 mg/m2 iv every 3 weeks. One cycle will be defined as 3 weeks. Treatment will be administered on an outpatient basis.

Trial Locations (1)

19104

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

Abramson Cancer Center at Penn Medicine

OTHER

NCT01773109 - Etirinotecan Pegol (NKTR-102) in NSCLC | Biotech Hunter | Biotech Hunter